Belite Bio, Inc

Ladies and gentlemen, thank you for joining us and welcome to the Be Light Bio first quarter 2026 earnings call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press star nine to raise your hand and star six to unmute. I will now hand the conference over to Julie Fallon. Please go ahead.

Good afternoon, everyone. Thank you for joining us. On the call today are Dr. Tom Lin, Chairman and CEO of BeLiveBio, Dr. Hendrik Scholl, Chief Medical Officer, Dr. Nathan Mata, Chief Scientific Officer, and Haoyang Zhang, Chief Financial Officer. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. And now I'll turn the call over to Dr. Lin. Dr. Lin?

Thank you, Julie. Good afternoon. Thank you for joining our first quarter 2026 financial results and updates. We have made exciting progress so far this year. We have received our phase three clinical study report in Q1, and without delay in April, we initiated our NDEA rolling submission to the FDA for Stargardt's disease. We're on track to complete the submission by the second quarter of this year. As we approach the completion of the rolling submission, we're also preparing for our commercial launch. We have hired all commercial leadership positions and continue to build up our teams in sales, market access, and medical affairs. We're also building out our commercial infrastructure, as well as engaging with the retinal community to raise awareness of startup disease. We are focused on preparing for a strong launch and looking forward to sharing more on our commercial planning in the future. In line with that commitment to bring Tenabent to patients around the world, This past quarter, we also announced that we have completed enrollment in our Phase 2-3 Dragon 2 clinical trial, evaluating telurban in Starr's disease. This trial enrolled 73 adolescents and adult subjects aged 12 to 20 years old from Japan, United States, and UK. This is a registration-enabling study to pursue approval in Japan. This is shaping up to be a pivotal year for Beelight as we begin our transition to a commercial stage company. We look forward to providing further updates on our work bringing therapies for retinal degenerative disease and significant unmet medical needs. I'll now turn over the presentation to Haoyan to discuss the financials. Haoyan.